Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of a Purified Standardised Bee Venom Preparation
This study is ongoing, but not recruiting participants.
First Received: December 9, 2005   Last Updated: July 16, 2008   History of Changes
Sponsor: Allergopharma Joachim Ganzer KG
Information provided by: Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier: NCT00263952
  Purpose

The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy


Condition Intervention Phase
Bee Venom Allergy
Biological: bee venom
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.

Resource links provided by NLM:


Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date: March 2003
Estimated Study Completion Date: April 2010
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of bee venom allergy,
  • Positive RAST for bee venom,
  • Positive skin prick test for bee venom

Exclusion Criteria:

  • Serious chronic diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263952

Locations
Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465
Sponsors and Collaborators
Allergopharma Joachim Ganzer KG
Investigators
Principal Investigator: Annemie Narkus, M.D. unaffiliated
  More Information

Additional Information:
No publications provided

Study ID Numbers: Al0202ig
Study First Received: December 9, 2005
Last Updated: July 16, 2008
ClinicalTrials.gov Identifier: NCT00263952     History of Changes
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:
Bee venom allergy
Specific immunotherapy

Additional relevant MeSH terms:
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on November 25, 2009